Background: Subcutaneous allergen immunotherapy with grass pollen allergoids has
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| INTRODUCTION
Allergen immunotherapy (AIT) has been comprehensively proven to be effective and safe in grass pollen-allergic patients 1,2 ; accordingly, grass pollen allergy is one of the main indications for AIT. 3 Grass pollen extracts are usually prepared from a mix of multiple grass species. The high cross-reactivity among different Pooideae species 4, 5 suggests that using a single species for preparing grass pollen extracts treatment should be effective and safe. [6] [7] [8] While this hypothesis is well supported, [9] [10] [11] some studies have found that a grass mix extract is more suitable for AIT. 12, 13 Different quantities of major allergens in the various extracts that have been used may be one possible explanation. According to the European Medicines Agency (EMA) guideline for allergen production and quality, 14 single allergen preparations can be adopted to investigate the safety and efficacy of homologous allergen groups. Single-grass pollen extracts from Phleum pratense (P. pratense) have elicited similar degree of basophil activation compared to mix-grass extracts, 15 extensive IgG4-induced cross-reactivity with other single-and mix-grass pollen extracts, 16 and reduced early and late skin response to P. pratense and 5-mix-grass extracts. 17 This activity can be attributed to high sequence identity of its group 1 (>91% and <95%) and group 5 allergens (>55% and <85%) with other members of the Poaceae family. 18, 19 A 6-grass pollen allergoid mixture consisting of equal parts of Holcus lanatus (H. lanatus), Dactylis glomerata (D. glomerata), Lolium perenne (L. perenne), P. pratense, Poa pratensis (P. pratensis), and Festuca pratensis (F. pratensis) (Allergovit â ) has also been proven to be effective and safe. 13 No studies have yet reported a comparison between the P. pratense allergoid and this 6-grass pollen allergoid mixture for clinical and immunological effects in grass pollen-allergic patients. The aim of this double-blind, placebocontrolled dose-finding study was to evaluate efficacy and safety of three different doses of a new grass pollen allergoid from P. pratense compared with placebo and to this 6-grass pollen allergoid mixture.
According to the EMA guidelines for AIT, 11 dose-finding studies have to be performed to establish a dose-response relationship for clinical efficacy. In such studies, provocation tests may be used as primary endpoints. 11, 20 Considering the positive results of previous studies, [21] [22] [23] the change in the weal size after an intracutaneous test (ICT) before and after treatment was chosen as the primary endpoint in this study. The Total Nasal Symptom Score (TNSS) is frequently used as an efficacy endpoint in AIT trials performed in an allergen exposure chamber (AEC). A recently published position paper of the European Academy of Allergy and Clinical Immunology (EAACI) has aimed to harmonize current concepts in AECs and to project unmet needs of these models. 24 In the context of controlled out-of-season allergen exposure in an AEC, the TNSS does not need to be combined with medication scores. 25, 26 Hence, in the present study, TNSS was chosen as a secondary endpoint.
| MATERIAL AN D METHODS
| Patients
Of the 190 patients screened, 102 subjects were randomized.
Inclusion criteria were as follows: both genders; age: 18-65 years;
IgE-mediated rhinoconjunctivitis to grass pollen allergens with con- 
| Interventions
This phase II study (EudraCT: 2011-000674-58) was conducted at eight sites in Germany. The study included 14 visits (screening visits S1
to S3, treatment visits T1 to T9 and follow-up visits FU1 and FU2; Figure 1). At Visit S1, patients were screened for study eligibility. Visits S2
and S3 took place after the grass pollen season between September and October 2012. At Visit S2, a pre-treatment ICT using two different active allergen doses was performed to assess the size of the skin reaction and to determine the optimal concentration for post-treatment retesting. At Visit S3, a pre-treatment TNSS was determined during provocation with grass pollen in the AEC. This optional visit was held at the AEC of the Fraunhofer-Institute ITEM (Hannover, Germany). On Visit T1, eligible subjects were randomized to one of the five treatment groups and received their first subcutaneous injection. After the end of all treatment visits, but before the start of the grass pollen season (January/February), the post-treatment TNSS was determined on Visit FU1 (optional). At the final Visit FU2, a post-treatment ICT with only one of the two active allergen doses, depending on the ICT reaction at Visit S2, was performed.
| Subcutaneous immunotherapy (SCIT)
The investigational medicinal product is a chemically modified 100%
P. pratense pollen allergen preparation (allergoid) for subcutaneous administration adsorbed to aluminium hydroxide, specified in therapeutic units (TU). Three of the five treatment groups received nine injections each (seven up-dosing and two maintenance doses) of the P. pratense allergoid up to a maximum of the standard-dose: 6000 TU, a three-fold higher dose: 18 000 TU or 1/10 of the highdose: 1800 TU. The up-dosing injections were administered weekly, followed by two maintenance doses administered after 14 and L. perenne, P. pratense, P. pratensis and F. pratensis), was also administered as seven increasing doses up to the standard-dose of 6000 TU followed by two maintenance doses of 6000 TU. The manufacturing processes applied for production of P. pratense allergoid and 6-grass allergoid preparations are comparable. 28 The procedure for the detection of major allergens in extracts used for the allergoid production is provided in the Supporting Information of the manuscript (Text S1). 
| Endpoints
| Intracutaneous testing
Intracutaneous testing was performed at Visit S2 and Visit FU2 on the dorsal side of both forearms using a 6-grass pollen allergen solution for ICT. In order to determine the optimal dose, 0. Medications that could interfere with ICT or AEC challenge had to be terminated before the procedure according to their half-lives.
| Immunological profile
At screening and post-treatment, P. pratense-specific total IgG and IgG 4 antibodies were assessed. 31 
| Safety assessment
Adverse events (AEs), serious AEs (SAEs), systemic reactions (SRs), clinical laboratory tests and vital signs were assessed. After each injection, subjects were observed for 6 hours and the size of local reactions (diameter in mm) 30 minutes after injection, peak expiratory flow (PEF) and vital signs were assessed. AEs were coded according to MedDRA, version 15.1 (http://meddra.org). SRs were graded according to the EAACI grading system. 3 
| Blinding and randomization
The randomization was performed blockwise, whereby the size of the blocks was unknown by the study sites. The investigators, the subjects and the personnel involved in the study remained blinded throughout the study until database lock.
| Statistics
During the study planning, the treatment effects, the variance of the primary endpoint and the shape of the dose-response curve were uncertain. It was unclear whether the desired power could actually be achieved in a fixed sample size design. The study was, therefore, performed with an adaptive interim analysis. 32 A closed testing system was applied to control the one-sided type I error rate within the interim analysis of a 1 =0.0102; that is, all tests at interim analysis were performed at a 1 . First, it was investigated whether there was any difference between placebo and the three active dose levels. If the corresponding null hypothesis could be rejected, then the null hypotheses, stating no difference between the placebo and two
active dose levels, were tested for all subsets of two active dose levels. For those active dose levels for which all related null hypotheses could be rejected, the null hypothesis of no difference between the active dose level and placebo was tested. The global hypotheses were tested by the Bartholomew test for unknown but common variances. The null hypotheses of the single doses of P. pratense versus placebo were tested by an analysis of covariance (ANCOVA) with the change of the size of the LPR as the dependent variable, the treatment group and centre as fixed effects, and the size of the LPR at baseline as a covariate. Treatment comparisons regarding the active comparator were performed in an exploratory manner without inclusion in the closed testing procedure. As all hypotheses were already rejected and all study objectives met at the interim analysis (P<.0102), the study was stopped early.
For assessment of differences of baseline parameters, the Wilcoxon test was applied, and for assessment of differences of safety variables, exploratory analyses were performed.
| Ethical conduct of the study
The study was conducted in Germany in accordance with the principles of the Declaration of Helsinki, the ICH guidelines for Good Clin- 3 | RESULTS
| Subjects
A total of 82 subjects were randomized to the active treatments and 20 subjects to placebo (Table 1) . One subject randomized to the standard-dose group did not receive any treatment. All of the other 101 randomized subjects were treated with at least one injection and therefore included in the Safety Set (SAF). Of them, 98 subjects had post-baseline efficacy assessments available and were included in the Full Analysis Set (FAS). Due to missing data, it was not possible to calculate the change from baseline in ICT LPR to post-treatment for five subjects; thus, 93 subjects were included in the primary efficacy analysis. The Per-Protocol Set comprised the 91 FAS subjects without major protocol violations. Participation in the AEC was not mandatory for study inclusion; hence, AEC data for 68 subjects were available. Figure 2 shows the disposition of subjects in the study. The key baseline demographic characteristics are shown in Table 1 . Most of these baseline data were comparable between the treatment groups, except for statistically significant differences in the duration of rhinoconjunctivitis between the P. pratense lowdose group and the placebo group (P<.05) and in the ICT LPR between the P. pratense high-and the low-dose groups (P<.05).
| Intracutaneous testing
Median changes from baseline in ICT LPR to post-treatment are shown in Figure 3 . Compared with the low-dose group, a slight further increase in the treatment effect was apparent for the subjects in the standard-dose group treated with 6000 TU. No additional effect was observed for the subjects in the high-dose group. The subjects randomized to the 6-grass pollen preparation showed changes comparable with the P. pratense standard-dose group. All of the global tests and all of the following pairwise comparisons showed significant effects of the active treatment groups compared with placebo (P<.001). Individual paired data of the ICT LPR before and after SCIT for every patient of the five treatment groups confirm limited changes for all subjects of the placebo group compared with large changes for most of the subjects in the active treatment groups ( Supporting Information, Fig. S1 ). The changes in EPR measured 15 minutes after ICT only showed statistically significant difference for the 6-grass active comparator-dose group compared with placebo (P<.05, data not reported). group. Due to the small number of subjects per treatment group, these differences were not statistically significant.
| Immunological evaluation
The median changes from baseline in the P. pratense-specific IgG 4
antibodies to post-treatment are shown in Figure 5 . All four active treatment groups showed a statistically significant increase in F I G U R E 4 Change of the baseline-adjusted area under the curve (AUC) of Total Nasal Symptom Score (TNSS). Median (interquartile range) decrease in AUC for the TNSS between the 2h provocation in the allergen exposure chamber at baseline and after allergen immunotherapy for all treatment groups (P=not significant). Number of patients: placebo, N=15; low-dose=13; standard-dose=14; highdose=10; 6-grass pollen=16 (total=68 of Full Analysis Set) IgG 4 response comparable to the P. pratense standard-dose group. A similar, statistically significant increase from baseline to final visit was also observed for P. pratense-specific IgG antibodies (data not reported).
| Safety and tolerability
Safety evaluation was performed in the SAF comprising of 101 subjects. A summary of the treatment-emergent AEs are reported in Table 2 . A total of 65 subjects experienced at least one AE. AEs with at least a possible relationship to the study medication were more frequent in the active treatment groups compared with the placebo group. Among the active treatment groups, a notable difference in terms of a three-fold higher number in subjects with AEs with at least a possible relationship to the study medication was observed in the 6-grass active comparator group compared with the P. pratense standard-dose group. It is also worthwhile to note that the number of subjects with local reactions in each of the treatment groups was similar to those with at least a possible relationship to the study medication. Subjects most frequently reported AEs belonging to the System Organ Class "General disorders and administration site conditions," and the most frequent Preferred Terms were "Injection site swelling" and "Injection site pruritus." Only four subjects had at least one SR related to the study medication: one subject in the high-dose group (PEF decrease), two in the 6-grass active comparator group ("Eye lid oedema" and "Oedema peripheral"), and one in the placebo group (PEF decreased). None of the SRs were rated grade II to IV according to the EAACI classification. No SAEs were reported. No changes were reported for laboratory tests and vital signs.
| DISCUSSION
This double-blind, placebo-controlled, dose-finding study is the first to investigate three doses of a newly developed P. pratense allergoid and the standard-dose (6000 TU) of the approved 6-grass pollen allergoid (Allergovit â ). 13, 33 Both allergoid preparations were found to contain group 1 and 5 allergens from grass pollen detected by specific mouse monoclonal antibodies at the expected positions ( Supporting Information, Fig. S2 ). The study was designed to investigate statistically significant differences after short-term SCIT (nine injections) of the four active treatment groups compared with placebo, but was not planned and powered to show significant differences between the active treatment groups for any of the efficacy endpoints. Hence, a relatively small number of subjects were randomized (n=102) and included in the FAS (n=98). The LPR resulting from the ICT was chosen as the primary endpoint of the study.
A measure of the TNSS over the 2 hour challenge duration in the AEC was the key secondary endpoint. It was optional for subjects to take this assessment, and hence, data for only 68 subjects were available for this analysis. Additional secondary endpoints were | 1451 placebo (P<.001). This clinical effect was mirrored by significant increases in P. pratense-specific IgG and IgG 4 levels and decreases in the TNSS. As the study was not powered to show statistically significant differences in the change from baseline in TNSS, the decrease in the TNSS observed did not reach statistical significance compared with placebo. Similarly, as the study was not planned to show significant differences between the active treatment groups for any of the efficacy endpoints, the same could not be established between the three doses of the P. pratense allergoid and the 6-grass pollen allergoid preparation. The safety profile of the P. pratense treatment groups was comparable to placebo thus conforming to the well-known high tolerability of allergoid preparations.
13,33
The first major aspect of this study is the use of LPR resulting from an ICT as a primary outcome measure. According to the EMA, provocation tests (skin, eye, nose, bronchi, allergen challenge chamber) may be used as primary endpoint in dose-finding studies. 11, 20 Martinez-Cocera et al. 23 parison, a decrease in the EPR appeared very late during treatment. 22 In another study by Durham et al., 21 clinical improvement was also accompanied by a marked decrease in the late skin response to intradermal allergen challenge, and this effect was maintained for up to 3 years after AIT discontinuation.
The use of an AEC is the second major aspect of this investigation. Historically, AEC has been used for testing anti-allergic medications, 43 AIT proof of concept and dose-finding studies. 44, 45 AEC is now also accepted by the EMA for AIT dose-finding studies.
11
Symptoms elicited by AEC exposure outside the pollen season proved to correlate with symptoms caused by natural pollen exposure. 46, 47 This method allows better control of the allergen exposure, eliminates the interference in data interpretation due to rescue medications and reduces the requirements for a high number of subjects to be included in a study. 20, 25, 26 The Fraunhofer AEC in Hannover is standardized and validated for exposure with grass pollen from D. glomerata to induce allergic symptoms in grass pollen-allergic patients. 29 In this study, different grass pollen species were used to investigate the endpoints, that is ICT (6-grass mix), AEC (D. glomerata) and IgG/IgG 4 (P. pratense) after AIT with either an allergoid of P. pratense or a 6-grass pollen mix.
Various studies suggest a comparable effect of any of the grass species of the Pooideae subfamily for AIT, based on inhibition of the IgE binding, 10 extensive cross-reactivity between the IgG 4 induction, 9,23 T cell cross-reactivity (stimulating T cell lines specific to group 1 or group 5 allergens of P. pratense) 9 or basophil inhibition assays. 15 Moreover, two clinical studies comparing a P. pratense extract with a grass mix found that the single species extract was at least clinically comparable in efficacy to the mix. 48, 49 But because both trials were not performed in a double-blind, double-dummy, or at least using a placebo-controlled design, the results may be considered to be only indicative of comparable clinical efficacy. Recently, Ramirez et al., showed a symptomatic response of grass allergy in subjects exposed to P. pratense in an AEC, despite the fact that the participants were recruited from a geographic area where P. pratense
is not present. This is indicative of high cross-reactivity within the species of this Pooideae subfamily. 8 Hence, in this study, the overall results in ICT, TNSS and IgG 4 may be considered to be comparable between the P. pratense allergoid and the 6-grass pollen allergoid preparations despite the use of the 6-grass mix for challenge tests ( Figures 3, 4 , and 5).
A deeper look into study outcomes also shows signs of extensive cross-reactivity of grass pollen allergens via similar IgG 4 titres at the standard-dose for the P. pratense allergoid and the 6-grass pollen allergoid preparations because of the use of 6-grass mix for challenge. 9 The induction of IgG 4 is an indirect evidence for the activation of allergen specific T cells during the course of AIT. 50, 51 In the present study, the low-dose of the P. pratense preparation was obviously not sufficient to activate all available T cells, thus leading to less IgG 4 production. However, it is surprising that we did not observe a further increase in IgG 4 at the high-dose, as dose-response AIT studies indicate that IgG 4 titres increase in a dose-dependent manner. 52 This unusual response could be attributed to a small number of subjects with high variability in IgG 4 titres ( Figure 5 ).
Clinical evidence also suggests that not all Pooideae grass epitopes with homology are cross-reactive. Archila et al. reported various degrees of minimally cross-reactive T cell epitopes from four different species within the Pooideae subfamily that showed no cross-reactivity to Phl p 1 and Phl p 5a epitopes. They concluded that a multiple-pollen allergoid system should be considered over a single-pollen allergoid for AIT. 53 Despite the equivalent dose, there was a three-fold increase in the number of local reactions in the 6-grass pollen allergoid group compared with the P. pratense standard-dose group. This was observed in an exploratory (not confirmatory) analysis. As the production processes as well as the amount of allergens were the same for both allergoid preparations, the three-fold increase in local reactions cannot be suitably explained. However, due to the fact that there was no significant difference in the number of SRs, it may be concluded that the P. pratense allergoid preparation is comparable in safety to the 6-grass pollen allergoid preparation. Taking into account the efficacy and safety endpoints, the standard-dose of 6000 TU of the new P. pratense allergoid is comparable with the marketed 6-grass pollen allergoid at equal dose. The significant decrease in the LPR to the ICT, the improvement of the TNSS and the increase in specific IgG 4 titres were comparable between these two preparations, thus suggesting that a single species grass pollen allergoid preparation could be sufficient and effective for AIT in grass pollen-allergic subjects.
Grass pollen is the major cause of pollinosis in many parts of the world, 6, 54 and AIT is the only potential disease-modifying treatment for allergic subjects. 55, 56 New grass pollen extracts could therefore have a big impact in the field of allergy treatments. In addition to finding the optimal dose for a new grass pollen extract derived from P. pratense in accordance with the current EMA guidelines, 11 this study demonstrates that efficacy and safety of this single species allergoid is comparable to the marketed 6-grass pollen allergoid for SCIT.
These results are highly valuable in the development of improved AIT products for the treatment of grass pollen-allergic subjects, although a further evaluation may be warranted using a combined symptom medication score as primary endpoint in a pivotal field study. 
